PILATESRETURN TO LIFE THROUGH CONTROLOG

Product Information

ESP009 (CSR 396/2004) This study compared the efficacy of 20 mg pantoprazole once daily with 150 mg twice daily ranitidine in healing of oesophagitis and freedom from GORD symptoms after treatment. Pantoprazole was superior to ranitidine in the treatment of key GORD symptoms. Similar results were shown by study FK3059, VMG306, FK3034, BGSA006, which also showed superiority of 20 mg pantoprazole compared to 300 mg ranitidine in the treatment of reflux symptoms. The tablets should be swallowed whole with liquid before a meal and should not be chewed or crushed. How does Controloc Control work? Controloc nu este recomandat pentru utilizare la copii deoarece nu s-a demonstrat eficienţa la copii sub vârsta de 12 ani. Atenționări:Conducerea vehiculelor sau folosirea utilajelor Dacă trebuie să urmaţi un tratament continuu cu medicamente de tip AINS şi luaţi Controloc deoarece prezentaţi un risc ridicat de a dezvolta complicaţii la nivelul stomacului şi intestinului. Orice risc ridicat trebuie evaluat în conformitate cu factorii dumneavoastră personali de risc, precum vârsta (peste 65 de ani), antecedente de ulcer stomacal sau duodenal sau de sângerări la nivelul stomacului şi intestinului. BF010 (CSR 298E/99) This study compared the efficacy of omeprazole 10 mg versus pantoprazole 20 mg at day 28 in patients without oesophagitis established by endoscopy. No day 14 data was available in the study report. In the non-prescription product setting, the patient would be self-referring to their physician if no symptomatic relief was obtained by day 14, making this study of limited value in the non-prescription context. Additionally, the usual starting dose for omeprazole in reflux disease is 20 mg; 10 mg omeprazole is not therapeutically equivalent to 20 mg pantoprazole. The study contained a treatment phase C; days 29-56, but again, this is not relevant to a non-prescription indication of no more than 28 days. Overall this study provides no relevant data analogous to the initial non-prescription medication period of up to 14 days. Additionally, in other studies efficacy of pantoprazole was compared to other PPIs (lansoprazole, esomeprazole) and it was found to be non-inferior to these PPIs in relieving symptoms of heartburn and acid regurgitation (Study VMG305 and M3-320).

to support clinical efficacy and safety, the application is based on the results of 17 clinical studies. None of the 6 above-mentioned studies provide data to support the proposed indication and treatment duration that could not be derived from the other 11 studies provided in the application. Therefore, the 6 above-mentioned studies do not provide clinical data which has genuine impact on the assessment of the application. Tell your doctor or pharmacist straight away. If possible take your medicine and this leaflet with you. There are no known symptoms of overdose. Obvyklá dávka je jedna tableta denně. Lékař může dávku zvýšit na dvě tablety denně. Doba léčenírefluxní esofagitidy je zpravidla 4 až 8 týdnů. Lékař vám sdělí, jak dlouho máte přípravek užívat. Informujte svého lékaře nebo lékárníka o všech lécích, které užíváte, které jste v nedávné době užíval(a) nebo které možná budete užívat, a to i o lécích, které jsou dostupné bez lékařského předpisu.

Dacă aveţi orice alte întrebări suplimentare cu privire la acest medicament, adresaţi-vă medicului dumneavoastră, farmacistului sau asistentei medicale. Compoziție Controloc 20 mg comprimate gastro-rezistente:- Substanţa activă este pantoprazolul. Fiecare comprimat gastro-rezistent conţine 20 mg de pantoprazol (sub formă de sesquihidrat de sodiu). Nota: Controloc nu este indicat in caz de acuze gastro-intestinale usoare cum ar fi dispepsia psihogena. inaintea inceperii tratamentului trebuie exclusa posibilitatea unui neoplasm gastric sau a unei boli neoplazice a esofagului deoarece tratamentul cu Controloc poate ameliora simptomele unui ulcer malign ceea ce intarzie diagnosticul. Diagnosticul de esofagita de reflux trebuie confirmat endoscopic. Ingredienti inactivi: carbonat de sodiu anhidru, manitol (=0,0036 BU), crospovidone, polividone K25, polividone K90, stearat de calciu, propilen glicol, metilhidroxipropilceluloza, polii(acid acrilic, acid metacrilic) (etil, metil/acrilat, metacrilat)s 1:1, polisorbat 80, lauril-sulfat de sodiu, trietil citrat, coloranti: E171, E172. Tell your doctor immediately, before or after taking this medicine, if you notice any of the following symptoms, which could be a sign of another, more serious, disease:

Před užitím přípravku Controloc 40 mg se poraďte se svým lékařem, lékárníkem nebo zdravotní sestrou: severe and/or persistent diarrhoea, because CONTROLOC Control has been associated with a small increase in infectious diarrhoea. Your doctor may decide that you need some tests. zvýšená hladina bilirubinu, zvýšená hladina tuků v krvi; prudký pokles kolujících bílých krvinek v krvi, spojený s vysokou horečkou. Strat superior: hipromeloză , povidonă K 25, dioxid de titan (E 171), oxid galben de fer (E172), propilenglicol, copolimer de etilacrilat şi acid metacrilic (1:1), polisorbat 80, lauril sulfat de sodiu, trietil citrat. The gastro-resistant tablets are yellow, oval, biconvex film-coated tablets imprinted with ?P20? on one side.Halucinaţii, confuzie (în special la pacienţii cu un istoric privind aceste simptome); nivel redus de sodiu în sânge, senzaţie de furnicături, usturime, senzaţie de înţepături, senzaţie de arsură sau amorţeală; nivele scăzute de potasiu care pot cauza slăbiciune musculară, spasme sau ritm cardiac anormal; spasme musculare sau crampe; nivele scăzute de calciu. Potisk:šelak, červený oxid železitý (E172), černý oxid železitý (E172), žlutý oxid železitý (E172), roztok amoniaku 30%.